Neuronetics Launches Upgrades of NeuroStar? Advanced Therapy for Mental Health
October 19, 2021 at 08:31 am EDT
Share
Neuronetics, Inc. announced the release of the latest evolution of their NeuroStar? Advanced Therapy system with upgraded equipment and features. NeuroStar? Advanced Therapy for Mental Health is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 4 million treatments delivered and thousands of lives transformed. In addition to a refreshed look, the NeuroStar and TrakStar? enhancements will allow healthcare professionals (HCPs) to streamline their ability to treat more patients. Included in the update is an improved motor threshold (MT) algorithm, Fast MT?, which reduces the number of steps to determine the recommended MT level, one of the key treatment settings. Clinicians can also automate the treatment pulse ramping profile with SoftStart?, which allows HCPs to easily add or remove a sequence of pulses during a treatment session to ramp to the prescribed treatment level. In addition, TrakStar upgrades will enable HCPs to electronically request a benefits investigation (BI) for new potential patients and then manage and view BI results directly from NeuroStar?s proprietary HIPAA-compliant TrakStar patient data management system. TrakStar, which was designed to increase productivity, safety and practice marketing, is an essential tool that helps practices manage patients throughout their treatment course and track their patient outcomes. It helps optimize time spent with patients and decreases time spent on paperwork and other administrative tasks. Additional added features in TrakStar include Scheduled Patient Outcome Measures, enabling offices to reduce staff time and gather clinical data from patients they wouldn?t otherwise receive, by scheduling automated patient questionaires. A limited release will occur with specific TrakStar Cloud customers in mid-October with a full release to follow in the U.S.
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.